124 related articles for article (PubMed ID: 2766758)
1. Effect of flosequinan in patients with acute-onset heart failure complicating acute myocardial infarction.
Schneeweiss A; Wynne RD; Marmor A
Crit Care Med; 1989 Sep; 17(9):879-81. PubMed ID: 2766758
[TBL] [Abstract][Full Text] [Related]
2. The effect of flosequinan in patients with heart failure of acute onset complicating acute myocardial infarction.
Schneeweiss A; Wynne RD; Marmor A
Int J Cardiol; 1989 Jul; 24(1):73-6. PubMed ID: 2668206
[TBL] [Abstract][Full Text] [Related]
3. The effect of flosequinan in patients with acute-onset heart failure complicating acute myocardial infarction.
Schneeweiss A; Wynne RD; Marmor A
Jpn Heart J; 1989 Sep; 30(5):627-34. PubMed ID: 2614925
[TBL] [Abstract][Full Text] [Related]
4. Flosequinan induces hemodynamic improvement in heart failure complicating acute myocardial infarction.
Schneeweiss A; Marmor A; Wynne RD
Herz; 1988 Aug; 13(4):259-62. PubMed ID: 3169679
[TBL] [Abstract][Full Text] [Related]
5. Flosequinan, a new vasodilator: systemic and coronary hemodynamics and neuroendocrine effects in congestive heart failure.
Cavero PG; De Marco T; Kwasman M; Lau D; Liu M; Chatterjee K
J Am Coll Cardiol; 1992 Dec; 20(7):1542-8. PubMed ID: 1452928
[TBL] [Abstract][Full Text] [Related]
6. Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors.
Gottlieb SS; Kukin ML; Penn J; Fisher ML; Cines M; Medina N; Yushak M; Taylor M; Packer M
J Am Coll Cardiol; 1993 Oct; 22(4):963-7. PubMed ID: 8409070
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of flosequinan, given over 3 days, evaluated by continuous hemodynamic monitoring.
Schneeweiss A; Plich M; Green T; Wynne RD; Marmor A
Cardiology; 1989; 76(3):201-5. PubMed ID: 2776141
[TBL] [Abstract][Full Text] [Related]
8. Cumulative hemodynamic response to short-term treatment with flosequinan (BTS 49465), a new direct-acting vasodilator drug, in severe chronic congestive heart failure.
Kessler PD; Packer M; Medina N; Yushak M
J Cardiovasc Pharmacol; 1988 Jul; 12(1):6-11. PubMed ID: 2459536
[TBL] [Abstract][Full Text] [Related]
9. Central and regional hemodynamic effects of flosequinan for congestive heart failure.
Haas GJ; Binkley PF; Carpenter JA; Leier CV
Am J Cardiol; 1989 Jun; 63(18):1354-9. PubMed ID: 2658526
[TBL] [Abstract][Full Text] [Related]
10. Effects of low-dose flosequinan on left ventricular systolic and diastolic chamber performance.
Starling MR
Am Heart J; 1994 Jul; 128(1):124-33. PubMed ID: 8017265
[TBL] [Abstract][Full Text] [Related]
11. Haemodynamic and neurohumoral effects of flosequinan in severe heart failure: similarities and differences compared with intravenous nitroglycerin therapy.
Dakak N; Makhoul N; Merdler A; Yechiely H; Kahana L; Halon DA; Schneeweiss A; Lewis BS
Eur Heart J; 1993 Jun; 14(6):836-44. PubMed ID: 8325314
[TBL] [Abstract][Full Text] [Related]
12. Acute and chronic effects of flosequinan on resting and exercise haemodynamics in congestive heart failure.
Thomas P; O'Gorman DJ; Sheridan DJ
Br J Clin Pharmacol; 1993 Dec; 36(6):539-46. PubMed ID: 12959270
[TBL] [Abstract][Full Text] [Related]
13. Long-term vasodilator treatment with flosequinan does not lead to hemodynamic tolerance or neurohormonal activation in severe heart failure.
Bartels GL; Remme WJ; Look MP; Kruijssen DA
J Card Fail; 1995 Mar; 1(2):117-25. PubMed ID: 9420641
[TBL] [Abstract][Full Text] [Related]
14. Flosequinan: a vasodilator with positive inotropic activity.
Corin WJ; Monrad ES; Strom JA; Giustino S; Sonnenblick ES; LeJemtel T
Am Heart J; 1991 Feb; 121(2 Pt 1):537-40. PubMed ID: 1990760
[TBL] [Abstract][Full Text] [Related]
15. Acute and long-term effects of flosequinan in patients with chronic cardiac failure.
Marchionni N; Moschi G; Di Bari M; Burgisser C; Fumagalli S; Boncinelli L; Tarantini F; Ferrucci L
Am Heart J; 1993 Jul; 126(1):147-54. PubMed ID: 8322657
[TBL] [Abstract][Full Text] [Related]
16. The central haemodynamic effects of a single intravenous dose of flosequinan in patients with severe heart failure.
Markus H; Cowley AJ
Eur J Clin Pharmacol; 1991; 40(6):535-8. PubMed ID: 1884731
[TBL] [Abstract][Full Text] [Related]
17. Flosequinan in heart failure: acute haemodynamic and longer term symptomatic effects.
Cowley AJ; Wynne RD; Stainer K; Fullwood L; Rowley JM; Hampton JR
BMJ; 1988 Jul; 297(6642):169-73. PubMed ID: 3044507
[TBL] [Abstract][Full Text] [Related]
18. Positive inotropic and hemodynamic properties of flosequinan, a new vasodilator, and a sulfone metabolite.
Falotico R; Haertlein BJ; Lakas-Weiss CS; Salata JJ; Tobia AJ
J Cardiovasc Pharmacol; 1989 Sep; 14(3):412-8. PubMed ID: 2476620
[TBL] [Abstract][Full Text] [Related]
19. Exercise capacity, hemodynamic, and neurohumoral changes following acute and chronic administration of flosequinan in chronic congestive heart failure.
Riegger GA; Kahles H; Wagner A; Kromer EP; Elsner D; Kochsiek K
Cardiovasc Drugs Ther; 1990 Oct; 4(5):1395-402. PubMed ID: 1980598
[TBL] [Abstract][Full Text] [Related]
20. Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan.
Moe GW; Rouleau JL; Charbonneau L; Proulx G; Arnold JM; Hall C; de Champlain J; Barr A; Sirois P; Packer M
Am Heart J; 2000 Apr; 139(4):587-95. PubMed ID: 10740139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
